<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35445730</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-2431</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Oncology reports</Title>
          <ISOAbbreviation>Oncol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>EGFR inhibition reverses epithelial‑mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">109</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/or.2022.8320</ELocationID>
        <Abstract>
          <AbstractText>Tamoxifen resistance remains a major obstacle in the treatment of estrogen receptor (ER)‑positive breast cancer. In recent years, the crucial role of the epithelial‑mesenchymal transition (EMT) process in the development of drug resistance in breast cancer has been underlined. However, the central molecules inducing the EMT process during the development of tamoxifen resistance remain to be elucidated. In the present study, it was demonstrated that tamoxifen‑resistant breast cancer cells underwent EMT and exhibited an enhanced cell motility and invasive behavior. The inhibition of snail family transcriptional repressor 1 (<i>Snail</i>) and twist family BHLH transcription factor 1 (<i>Twist</i>) reversed the EMT phenotype and decreased the tamoxifen resistance, migration and invasion of tamoxifen‑resistant breast cancer cells. In addition, it was observed that the inhibition of epidermal growth factor receptor (EGFR) reversed the EMT phenotype in tamoxifen‑resistant MCF7 (MCF‑7/TR) cells via the downregulation of <i>Snail</i> and <i>Twist</i>. Notably, the EGFR inhibitor, gefitinib, decreased tamoxifen resistance, migration and invasion through the inhibition of <i>Snail</i> and <i>Twist</i>. On the whole, the results of the present study suggest that EGFR may be a promising therapeutic target for tamoxifen‑resistant breast cancer. Moreover, it was suggested that gefitinib may serve as a potent novel therapeutic strategy for breast cancer patients, who have developed tamoxifen resistance.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Takeda</LastName>
            <ForeName>Tomoya</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacotherapy, Kindai University School of Pharmacy, Higashiosaka, Osaka 577‑8502, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsubaki</LastName>
            <ForeName>Masanobu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacotherapy, Kindai University School of Pharmacy, Higashiosaka, Osaka 577‑8502, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuda</LastName>
            <ForeName>Takuya</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacotherapy, Kindai University School of Pharmacy, Higashiosaka, Osaka 577‑8502, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kimura</LastName>
            <ForeName>Akihiro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacotherapy, Kindai University School of Pharmacy, Higashiosaka, Osaka 577‑8502, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jinushi</LastName>
            <ForeName>Minami</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacotherapy, Kindai University School of Pharmacy, Higashiosaka, Osaka 577‑8502, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Obana</LastName>
            <ForeName>Teruki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Kindai University Hospital, Osakasayama, Osaka 589‑8511, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takegami</LastName>
            <ForeName>Manabu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Kindai University Hospital, Osakasayama, Osaka 589‑8511, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishida</LastName>
            <ForeName>Shozo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacotherapy, Kindai University School of Pharmacy, Higashiosaka, Osaka 577‑8502, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Oncol Rep</MedlineTA>
        <NlmUniqueID>9422756</NlmUniqueID>
        <ISSNLinking>1021-335X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>094ZI81Y45</RegistryNumber>
          <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013629" MajorTopicYN="Y">Tamoxifen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ER‑positive breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Snai1</Keyword>
        <Keyword MajorTopicYN="N">Twist</Keyword>
        <Keyword MajorTopicYN="N">epidermal growth factor receptor</Keyword>
        <Keyword MajorTopicYN="N">epithelial‑mesenchymal transition</Keyword>
        <Keyword MajorTopicYN="N">gefitinib</Keyword>
        <Keyword MajorTopicYN="N">tamoxifen resistance</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>8</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35445730</ArticleId>
        <ArticleId IdType="doi">10.3892/or.2022.8320</ArticleId>
        <ArticleId IdType="pii">109</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
